Company Profile
Context Therapeutics Stock Price, News & Analysis
- Ticker:
- CNTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.62 USD (+1.34%)
Close
Last updated: July 27, 2026
222M USD
Market cap
Why the stock is moving
As of Jul 27, 2026, CNTX closed up 1.34% at $0.6223. No new same-company headline was identified in the current news window.
Company overview
Business overview
Context Therapeutics is a biopharmaceutical company focused on immuno-oncology and cell-signaling pathways in solid tumors. Its story centers on whether a targeted approach can improve cancer treatment outcomes.
Geographic Base and Sector Classification
Context Therapeutics is headquartered in the United States and listed on NASDAQ. It sits in small-cap oncology biotechnology.
Business Model Characteristics
The business depends on clinical validation, strategic focus, and capital discipline while it advances a narrow pipeline. Investors generally watch early data and program prioritization.
Position Within the Biotechnology Landscape
Context occupies a specialized oncology niche within biotech. It is a catalyst-sensitive small-cap story where proof-of-concept matters greatly.
Future catalysts
Context Therapeutics’s catalysts are its oncology programs and any update that shows the company can still build a credible immuno-oncology story. The next data step matters because the platform is still early.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
LEGN · Source: Legend Biotech Corporation
- 03
- 04
- 05
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Context Therapeutics (CNTX)?
Context Therapeutics (CNTX) most recently closed at 0.62 USD, a +1.34% move versus the previous session.
What is the market cap of Context Therapeutics (CNTX)?
Context Therapeutics currently has a market capitalization of 222M USD on BioPharmSignal.
What does Context Therapeutics do?
Context Therapeutics is a biopharmaceutical company focused on immuno-oncology and cell-signaling pathways in solid tumors. Its story centers on whether a targeted approach can improve cancer treatment outcomes.
On which exchange is CNTX stock listed?
Context Therapeutics (CNTX) is associated with NASDAQ, United States, Biopharma.
What is Context?
Context Therapeutics’s catalysts are its oncology programs and any update that shows the company can still build a credible immuno-oncology story.
Which conditions is Context Therapeutics targeting with Context?
Context Therapeutics is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Context Therapeutics describe recent progress with Context?
Context Therapeutics’s catalysts are its oncology programs and any update that shows the company can still build a credible immuno-oncology story.
What is Therapeutics?
Context Therapeutics is a biopharmaceutical company focused on immuno-oncology and cell-signaling pathways in solid tumors.